Myopia (or near-sightedness) in children is a highly prevalent vision condition. It is estimated that the worldwide prevalence will reach about 50% by the...
Qfitlia (Fitusiran), a novel siRNA-based treatment for haemophilia has received FDA approval. It is a small interfering RNA (siRNA) based therapeutic that interfere with natural anticoagulants such as...
Concizumab (commercial name, Alhemo), a monoclonal antibody was approved by the FDA on 20 December 2024 for prevention of bleeding episodes in patients with...
Ryoncil has been approved for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), a life-threatening condition that may result from blood stem cell transplantation...
On 11 October 2024, Hympavzi (marstacimab-hncq), a human monoclonal antibody targeting “tissue factor pathway inhibitor” received US FDA’s approval as a new drug for...
“Hearing Aid Feature” (HAF), the first OTC hearing aid software has received marketing authorisation by the FDA. Compatible headphones installed with this software serve...